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In the last 20 years, the field of cellular and molecular oncology has been born and has moved its 
first steps, with an increasingly rapid pace. Hundreds of oncogenic and oncosuppressive signaling 
cascades have been characterized, facilitating the development of an ever more refined and 
variegated arsenal of diagnostic and therapeutic weapons. Furthermore, several cancer-specific 
features and processes have been identified that constitute promising therapeutic targets. For 
instance, it has been demonstrated that microRNAs can play a critical role in oncogenesis and 
tumor suppression. Moreover, it turned out that tumor cells frequently exhibit an extensive 
metabolic rewiring, can behave in a stem cell-like fashion (and hence sustain tumor growth), 
often constitutively activate stress response pathways that allow them to survive, can react to 
therapy by engaging in non-apoptotic cell death programs, and sometimes die while eliciting 
a tumor-specific immune response. In this Perspective article, we discuss the main issues 
generated by these discoveries that will be in the limelight of molecular and cellular oncology 
research for the next, hopefully few years.
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miRNA ANd cANceR
In 2002, the laboratory lead by Croce (2009) found that two non- 
protein-coding RNA (actually miRNA) genes, miR-15a and miR-
16-1, map to a region of chromosome 13 (13q14) that is frequently 
deleted in chronic lymphocytic leukemia (CLL) and that miR-15a 
and miR-16-1 are indeed lost in approximately 70% of CLL cases 
(Calin et al., 2002). This seminal work has paved the way to the 
elucidation of the multifaceted role of miRNAs in cancer. Later, 
it has been shown that miRNAs like miR-15a and miR-16-1 exert 
oncosuppressive functions by negatively regulating the expression 
of oncogenes such as the anti-apoptotic protein BCL2 (Cimmino 
et al., 2005). Similarly, members of the let-7 family of miRNAs, whose 
expression is lost in lung and breast cancer as well as in other solid and 
hematological malignancies, act as tumor suppressors by inhibiting 
the expression of RAS (Johnson et al., 2005). Of note, there are also 
miRNAs that promote oncogenesis by targeting oncosuppressors. 
For instance, members of the miR-17-92 cluster as well as miR-21, 
which are upregulated in multiple hematopoietic and solid tumors, 
inhibit phosphatase and tensin homolog (PTEN; Meng et al., 2007; 
Mendell, 2008).
In most cases, the deregulation of miRNAs derives from genetic 
defects (e.g., deletions, point mutations) in miRNA genes, in turn 
resulting in aberrant expression levels. However, there are addi-
tional mechanisms that provoke miRNA deregulation and by which 
miRNA can contribute to cancer. For instance, the miR-17-92 cluster 
is transactivated by MYC, an oncoprotein that is often overexpressed 
in cancer (O’Donnell et al., 2005). In this context, miR-17-92 func-
tions as an oncogenic effector of MYC. The   expression of miRNAs 
During the last decade, tremendous advances have been made 
toward an increasingly more precise understanding of cancer at 
both the cellular and molecular levels. It has been shown that in 
specific cellular settings, microRNAs (miRNAs) can exert bona fide 
oncogenic or oncosuppressive functions (Croce, 2009) and that 
tumor cells often, if not always, exhibit an extensive metabolic 
reprogramming (Kroemer and Pouyssegur, 2008); cancer stem cells 
(CSC) have been extensively studied (Visvader and Lindeman, 
2008); the importance of oncogene/non-oncogene addiction (Luo 
et al., 2009), and of immunogenic cancer cell death (Zitvogel et al., 
2010) has been established; and novel programmed cell death 
(PCD) modalities have been characterized (Vandenabeele et al., 
2010), just to mention a few examples (Figure 1). This knowl-
edge is rapidly being translated into ever more reliable diagnostic 
and prognostic biomarkers as well as into a broad array of new 
therapeutic tools. Moreover, the great promises that personalized 
anticancer strategies held at the end of the 1990s have turned 
into a clinically exploitable reality. Still, there remain multiple 
unresolved issues. For instance, how can we exploit the biology 
of CSC to render them sensitive to therapy? How can we trigger 
the immunogenic death of tumor cells and circumvent resistance? 
How can the tumor–stroma interaction be targeted for developing 
scarcely toxic yet highly efficient anticancer strategies? These are 
only some of the questions that will drive the work of cellular and 
molecular oncologists for the next few years. We must concentrate 
our efforts to answer these great challenges, as the underlying fun-
damental knowledge will undoubtedly sustain the development 
of   revolutionary clinical applications.
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this phenomenon, also known as Warburg effect, is not   universally 
applicable  to  all  cancers,  it  is  sufficiently  prevalent  for  being 
  clinically exploited to image cancer by 2-(18F)-fluoro-2-deoxy-d-
glucose (FDG) based positron emission tomography (FDG–PET; 
Kroemer and Pouyssegur, 2008). Since then, several other metabolic 
alterations have been identified in cancer cells. Nevertheless, until 
recently, the Warburg effect and other cancer-specific metabolic 
defects have been viewed as a mere epiphenomenon of and not as 
an active contributor to tumorigenesis.
This has gradually changed in the past decade, driven by the 
milestone discovery that germline mutations in two enzymes of the 
Krebs cycle, namely fumarate hydratase (FH) and succinate dehy-
drogenase (SDH), are associated with an increased risk of tumori-
genesis (Gottlieb and Tomlinson, 2005). Initially, the reason why FH 
and several genes coding for SDH subunits (i.e., SDHB, SDHC, and 
SDHD) behave as classical oncosuppressive genes was obscure. Then, 
Selak et al. (2005) and Pollard et al. (2005) independently demon-
strated that succinate and fumarate, accumulating in conditions of 
SDH and FH deficiency, respectively, inhibit prolyl hydroxylases in 
the cytosol leading to stabilization and activation of the oncoprotein 
HIF1α (Pollard et al., 2005; Selak et al., 2005). These works founded 
the concept of “oncometabolites,” i.e., metabolites that are able to 
drive tumorigenesis, and paved the way to the study of metabolic 
alterations as etiological determinants in cancer. The importance of 
this discovery is further corroborated by the long list of metabolic 
alterations that are being investigated as potential target for antican-
cer therapies (Kroemer and Pouyssegur, 2008). Thus, during the last 
decade, promising results have been obtained not only by targeting 
glycolysis (Bonnet et al., 2007; Simons et al., 2007) and the HIF1 
signaling pathway (Brizel and Esclamado, 2006; MacKenzie et al., 
2007) but also by modulating fatty acid synthesis, which is often 
exacerbated in cancer cells, reflecting their intense need for building 
blocks to sustain proliferation (Hatzivassiliou et al., 2005; Beckers 
et al., 2007), and other metabolic circuitries (Pouyssegur et al., 2006).
Additional metabolic alterations that selectively characterize cancer 
cells will surely be elucidated in the forthcoming years, hopefully lead-
ing to the development of new, potent anticancer compounds. In this 
context, it will be most interesting to see metabolomic research applied 
to molecular oncology and in particular to understand whether malig-
nant cells are characterized by metabolomic profiles that vary during 
tumor progression and hence can be used for a more precise tumor 
grading. Of note, cancer-associated metabolic reprogramming and 
the underlying molecular modifications are intimately linked to all 
other hallmarks of tumor cells (as defined by Hanahan and Weinberg, 
2000) including their limitless proliferative potential, self-sufficiency 
in growth signals, as well as their capacity to evade apoptosis, sustain 
angiogenesis, invade nearby tissues, and generate distant metastases 
(Kroemer and Pouyssegur, 2008). The great challenge in this respect is 
to identify clinically useful compounds that “double-hit” cancer cells, 
i.e., agents that rectify the metabolic alterations of cancer cells while 
simultaneously inhibiting one (or more) of their malignant features.
cANceR stem cells
It is well known that tumors exhibit a high degree of internal het-
erogeneity, with cells displaying distinct proliferative, differentiative, 
and functional capacities (Heppner and Miller, 1983). At least two 
theories have been proposed to account for tumor heterogeneity, 
can also be compromised by epigenetic events, such as promoter 
hypermethylation at CpG islands. This is the case of miR-127, an 
oncosuppressive miRNA that inhibits the oncogene BCL6 and that 
is frequently silenced in bladder tumors owing to promoter hyper-
methylation (Saito et al., 2006). Intriguingly, some miRNAs such 
as miR-29, miR-148a, and miR-148b have recently been shown to 
modulate promoter methylation by targeting DNA methyltrans-
ferases (DNMTs; Croce, 2009; Garzon et al., 2009).
Thus, important insights into the role of miRNAs in cancer patho-
genesis have been provided during the past 10 years. This caused a 
major leap forward in molecular and cellular oncology, leading to 
the development of promising clinically oriented applications. For 
instance, Kota et al. (2009) have recently demonstrated that MYC-
driven hepatocellular carcinomas (HCCs) regress in vivo upon the 
delivery of miR-26a, an miRNA that is normally expressed at high 
levels in diverse tissues but downregulated in HCC cells. In addition, 
efforts have been spent toward the understanding of the prognostic 
and predictive values of miRNA signatures in cancer (Ryan et al., 2010).
In this specific area of molecular and cellular oncology, there are 
at least two great challenges for the upcoming years, besides the iden-
tification of novel cancer-relevant miRNAs and their mode of action. 
First, based on large clinical studies, it will be important to validate the 
prognostic or predictive value of single miRNAs or of miRNA signa-
tures, as this will ameliorate the understanding of disease progression 
and allow for patient stratification and personalized therapy. Second, 
it will be critical to understand how miRNAs and anti-miRNAs, which 
currently hold great promises as highly specific and hence relatively 
safe therapeutic agents, should be targeted to tumor cells in vivo.
cANceR-specific metAbolic AlteRAtioNs
In the 1920s, the Nobel Prize winner Otto Warburg discovered 
that a large proportion of cancer cells display a specific metabolic 
alteration, i.e., they maintain high rates of glycolysis even in the 
presence of a normoxic environment (aerobic glycolysis). Though 
Figure 1 | The great discoveries of the last decade of molecular and 
cellular oncology research. MIRs, microRNAs; PCD, programmed cell death.www.frontiersin.org  March 2011  | Volume 1  | Article 1  |  3
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therapy of CSCs by triggering the differentiation program. This 
approach is exemplified by the work of Piccirillo et al. (2006), who 
could attenuate the tumor-forming capacity of CD133+ glioblas-
toma CSCs in vivo by inducing their differentiation into astrocyte-
like cells with bone morphogenic proteins (BMPs).
Although substantial evidence on the existence of CSCs has accu-
mulated during the past 10 years, there are still a number of critical 
issues that remain to be addressed. This is due not only to the elusive 
nature of CSCs but also to technical problems with their purification. 
One great challenge to CSC research is therefore the development of 
more refined techniques for CSC isolation, which in turn will allow 
to answer several other hitherto unresolved questions. First, is there a 
CSC-specific marker (or a combination of markers) that is common 
to all tumors of the same histological type? Second, can this combina-
tion be exploited for selectively targeting CSC while sparing normal 
stem cells? Moreover, there is an increasing interest in the possibility 
that solid CSCs not only may be hierarchically distinct from other 
tumor cells but also may occupy a CSC-restricted microenviron-
ment, in which they would engage in preferential relationships with 
cancer-associated stromal cells including fibroblasts, macrophages, 
and endothelial cells, which perhaps would contribute to CSC self-
renewing capabilities as well as to their resistance to therapy. Recent 
findings by Calabrese et al. (2007) and Bao et al. (2006b) demonstrate 
that glioma CD133+ CSCs (but not CD133−) cells can form highly 
vascular brain tumors in mice, a process that can be inhibited by beva-
cizumab, a vascular endothelial growth factor (VEGF)-neutralizing 
antibody. One of the most challenging issues for the upcoming years 
will be to determine whether solid CSCs do indeed occupy a restricted 
niche in the tumor architecture and whether there is the possibility 
to selectively target this niche for therapy.
oNcogeNe ANd NoN-oNcogeNe AddictioN
During the past two decades, our understanding of the patho-
genesis of cancer has tremendously been ameliorated, and it is 
now  clear  that  tumorigenesis  constitute  a  complex,  multistep 
process during which cells progressively acquire a common set 
of features that underlie their malignancy. These characteristics 
include the abovementioned hallmarks of tumor cells proposed 
by Hanahan and Weinberg (2000) as well as traits that have more 
recently been identified, such as the ability of cancer cells to escape 
immune surveillance, an extensive metabolic rewiring (Kroemer 
and Pouyssegur, 2008), and alterations in the autophagic machin-
ery (Morselli et al., 2009). Most of these features can be ascribed 
to genetic or epigenetic events that can bring about the gain-of-
function, amplification, or overexpression of oncogenes and/or the 
loss-of-function, deletion, or silencing of oncosuppressor genes 
(Hahn and Weinberg, 2002). In addition to these major altera-
tions, there appear to be several low-frequency changes that con-
tribute to tumorigenesis (Greenman et al., 2007), suggesting that 
each cancer is characterized by a specific and complex combination 
of genetic and epigenetic alterations that underlie the malignant 
phenotype. This enormous complexity and heterogeneity consti-
tutes an obvious problem for anticancer therapy, as it is difficult 
to appreciate which are the critical nodes that should be targeted 
to reverse malignancy (via cell death, senescence, or differentia-
tion). This picture is further complicated by the fact that cancer 
cells also exhibit a number of phenotypes that are not responsible 
the clonal evolution (Nowell, 1976), and the CSC (Reya et al., 2001) 
models. The former postulates that a mutant population of cancer 
cells acquires a proliferative advantage and drives tumorigenesis 
(Nowell, 1976). The latter, which has been put forward much later 
and for which convincing evidence has accumulated only during 
the last decade, proposes a hierarchical organization of cancer cells, 
in which a subpopulation of stem-like cells sustains tumor growth 
(Reya et al., 2001). These models are not mutually exclusive. Barabe 
et al. (2007) showed that leukemia CSCs can evolve with time from a 
primitive type to one containing rearranged immunoglobulin genes, 
implying that CSCs themselves can undergo clonal evolution. The 
frequency of CSCs is highly variable, ranging from less than 1% to the 
vast majority of cells (Hewitt, 1958). Notably, CSCs do not necessarily 
match cancer-initiating cells and do not necessarily derive from the 
transformation of normal stem cells (Visvader and Lindeman, 2008).
Although the first evidence for CSCs was obtained in murine 
models of acute myeloid leukemia (AML; Lapidot et al., 1994), it 
has now become clear that this model applies to multiple (though 
perhaps not all) solid tumors. One of the first demonstrations that 
tumor-initiating cells can be purified from solid malignancies came 
from the work of Al-Hajj et al. (2003) in breast cancer. In this context, 
it should be noted that the CSC phenotype (with regard to surface 
and intracellular markers) may not necessarily be uniform across 
tumor types or even cancers of the same histological origin. Still, 
the surface markers described so far by different groups for the same 
tumor type exhibit some overlap, which has allowed for the iden-
tification of some molecules that might be exploited (with highly 
variable success rates) for the purification of CSCs. These include 
the ATP-binding cassette family members ABCG2 and ABCG5, 
aldehyde dehydrogenase 1 (ALDH1), the epithelial cell adhesion 
molecule EpCAM (ESA, TROP1) as well as the cell surface proteins 
CD24, CD44, CD90, and CD133 (Visvader and Lindeman, 2008).
The existence of CSCs has far reaching clinical and therapeutic 
implications. Given their tumor-initiating capability, CSCs must 
be eradicated to ensure long-term disease-free survival to patients. 
However, this is complicated by multiple facets of CSC biology. 
First, in some instances, CSCs enter a dormant, non-proliferative 
state that render them more resistant to radio- and chemotherapy 
(Ishikawa et al., 2007). Second, CSCs often acquire active mecha-
nisms, for instance a particularly efficient DNA damage response, 
to resist anticancer therapy (Bao et al., 2006a). Third, CSCs can 
lose their sensitivity to treatment upon clonal evolution (Visvader 
and Lindeman, 2008). Intriguingly, some reports suggest that there 
is the possibility to selectively target the CSC compartment while 
sparing normal stem cells. Guzman et al. (2005) demonstrated that 
the natural compound parthenolide induces robust apoptosis in 
primary human AML but not normal hematopoietic cells, with an 
exquisite preference for the progenitor and stem cell populations. 
Similarly, Morrison’s laboratory found that rapamycin, an inhibi-
tor of the central cell regulator mechanistic target of rapamycin 
(MTOR), selectively targets leukemia-initiating cells that arise upon 
PTEN deletion (via MTOR overactivation) while sparing normal 
hematopoietic stem cells (HSCs; Yilmaz et al., 2006; Lee et al., 2010). 
CD44, which is required for the function and/or survival of CSCs 
but not of HSCs, has also been pointed to as a putative target for 
CSC-targeting anticancer strategies (Jin et al., 2006). Finally, some 
successful attempts have been made to decrease the resistance to Frontiers in Oncology  | Molecular and Cellular Oncology    March 2011  | Volume 1  | Article 1  |  4
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to which extent this phenomenon is conserved across distinct types 
of cancer. It will also be particularly interesting to see the results of 
clinical trials based on non-oncogene addiction inhibitors alone or 
in combination with classic anticancer drugs.
Novel pAthwAys of pRogRAmmed cell deAth ANd the 
immuNogeNic deAth of cANceR cells
For decades, developmental and pathological PCD was believed 
to be executed by predominantly apoptotic mechanisms and was 
associated with the morphological and biochemical manifestations 
of apoptosis (e.g., pyknosis, karyorrhexis, blebbing, caspase activa-
tion; Galluzzi et al., 2007; Kroemer et al., 2007, 2009). Conversely, 
necrosis was generally regarded to as a merely accidental proc-
ess (Vandenabeele et al., 2010). Along similar lines, it was firmly 
believed that the apoptotic death of cancer cells that respond to 
radio- and/or chemotherapy would be unable elicit an immune 
response (i.e., it would be immunologically silent) or sometimes 
even would actively inhibit the activation of the immune system 
(i.e., it would be tolerogenic), as opposed to the well known pro-
inflammatory nature of necrotic cell death (Zitvogel et al., 2010). 
During the past few years, it has become clear that both these pre-
conceived ideas represent gross oversimplifications.
Thus, several lines of evidence have been collected demonstrat-
ing that: (i) necrosis can be a precisely regulated process, both in 
its occurrence and in its course, (ii) developmental PCD can be 
mediated by the molecular machinery for necrosis, and that (iii) 
PCD can manifest with morphological traits of necrosis, including 
organelle swelling, dilatation of the nuclear membrane, chroma-
tin condensation into small, irregular, circumscribed patches, and 
increased cell volume (oncosis), culminating in the rupture of the 
plasma membrane (Golstein and Kroemer, 2007; Vandenabeele et al., 
2010). Circumstantial evidence suggesting that necrosis can occur 
in a regulated fashion has started to accumulate at the end of the 
twentieth century, when first Laster et al. (1988) and then Vercammen 
et al. (1998a,b) reported that the engagement of death receptors 
including tumor necrosis factor receptor 1 (TNFR1) and CD95/FAS 
can initiate both the apoptotic and the necrotic subroutine of cell 
death, depending on cell type and the presence of caspase inhibi-
tors (e.g., Z-VAD.fmk). Nevertheless, most doubts on the existence 
of programmed necrosis have not been cleared until 2005, when 
Degterev et al. (2005, 2008) have reported the discovery of necrosta-
tin 1, a small molecule that exerts potent anti-necrotic effects in 
vitro and in vivo by targeting the TNFR1-associated kinase receptor 
interacting protein kinase 1 (RIPK1, also known as RIP1) . In this 
context, Degterev et al. (2005) introduced the term “necroptosis” to 
indicate the regulated form of necrosis that is induced by TNFR1 
ligation. The discovery of necrostatin 1 has quickly been followed by 
the characterization of other necrostatins (Wang et al., 2007; Degterev 
et al., 2008), which altogether have ignited two novel and very intense 
fields of necrosis-related research. First, necrostatins have provided 
investigators with a convenient tool for disentangling the molecular 
network that underlies necroptosis, leading in a few years to the char-
acterization of several factors that are required for the initiation and 
execution of TNFR1-induced programmed necrosis, including the 
tumor suppressor cylindromatosis (CYLD; Hitomi et al., 2008) and 
the RIP1-related kinase RIP3 (Cho et al., 2009; He et al., 2009; Zhang 
et al., 2009). Second, necrostatins have allowed for the   demonstration 
for initiating tumorigenesis, including DNA damage/replication, 
proteotoxic, mitotic, metabolic, and oxidative stress, which have 
collectively been referred to as “stress phenotypes” (Luo et al., 2009). 
Although some of these phenotypes are not restricted to malignant 
cells and can be observed in cancer-unrelated settings (e.g., chronic 
inflammation), tumor cells must activate support mechanisms in 
order to tolerate these conditions and oncogenic stress.
The activation of oncogenes and/or the loss of oncosuppressor 
genes are required not only for tumorigenesis but also for the sur-
vival of established tumors. This concept is widely known under the 
name of “oncogene addiction” and has elegantly been demonstrated 
by experiments aimed at either suppressing oncogene activity or 
restoring tumor suppressor function. For instance, MYC-driven pap-
illomas, lymphomas, and osteosarcoma have been shown to regress 
upon MYC withdrawal in vivo (Felsher and Bishop, 1999; Pelengaris 
et al., 1999; Jain et al., 2002). Along similar lines, the addiction to 
HRAS, BCR-ABL, and KRAS has been demonstrated in murine mod-
els of melanoma, leukemia, and colorectal cancer (Shirasawa et al., 
1993; Chin et al., 1999; Huettner et al., 2000). Moreover, reintro-
duction of TP53 has recently been shown to induce the regression 
of TP53-deficient tumors (Ventura et al., 2007; Xue et al., 2007). 
In the past decade, several oncoprotein inhibitors have been devel-
oped and entered the clinical practice including imatinib (targeting 
BCR–ABL), gefitinib and erlotinib (both inhibiting the epidermal 
growth factor receptor, EGFR), and trastuzumab (targeting HER2; 
Luo et al., 2009). Conversely, no drugs have been released to date that 
would restore oncosuppressor functions, perhaps because it is much 
more difficult to achieve the pharmacological reactivation of deficient 
genes/proteins than the inhibition of hyperactivated oncogenes.
Cancer cells are not only addicted to oncogenes. Partially owing to 
the high levels of stress that tumor cells must continuously endure and 
partially because of the extensively rewired pathways that result from 
the oncogenic process itself, it appears that malignant cells depend for 
their survival on the activity of a wide array of genes and functions that 
are not inherently oncogenic per se. The concept of “non-oncogene 
addiction” has been first formulated by Solimini et al. (2007) and has 
profound therapeutic implications. First, since tumors are character-
ized by a whole compendium of genetic alterations (among which 
only a few involve bona fide oncogenes and oncosuppressor genes), 
there is ample space for developing pharmacological agents that exert 
anticancer effects by reversing non-oncogene addiction. Second, there 
is an entire category of cell-extrinsic pathways that underlie non-
oncogene addiction, including vascular and stromal functions. While 
targeting these circuitries might prove more difficult for selectivity 
issues (e.g., it might be complicated to target tumor vessels while spar-
ing normal ones), it also constitutes a rather promising approach, since 
normal cells that support tumors tend to be genetically more stable 
than cancer cells and hence less prone to evolve toward drug resist-
ance (Solimini et al., 2007; Luo et al., 2009). Non-oncogene addiction 
mainly represents the dependency of cancer cells on stress support 
pathways. Thus, at least on theoretical grounds it would be possible 
to selectively kill tumor cells by either inhibiting these cytoprotec-
tive mechanisms or by exacerbating stress. Several lines of evidence 
obtained in preclinical models suggest that non-oncogene addiction 
constitutes a clinically exploitable phenomenon (Solimini et al., 2007; 
Luo et al., 2009). One major challenge for the forthcoming decade is 
to refine our knowledge of non-oncogene addition and to understand www.frontiersin.org  March 2011  | Volume 1  | Article 1  |  5
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By binding to a hitherto uncharacterized receptor on the surface 
of dendritic cells (DCs), ecto-CRT functions as a potent “eat-me” 
signal, thus enhancing the uptake of antigens from apoptotic cells 
and stimulating a DC-driven T cell-mediated immune response 
(Martins et al., 2010). Several other signals that are required for 
immunogenic cell death have been decoded during the past few 
years (Zitvogel et al., 2010), including “find-me” signals that are 
released by dying cells and stimulate the chemotaxis of immune 
cells, thereby recruiting them at the site of cell death (e.g., ATP, UTP; 
Ghiringhelli et al., 2009; Aymeric et al., 2010). Intriguingly, not all 
“find-me” and “eat-me” signals actively prime immune cells and, in 
addition, some dying cells expose or release molecules that deliver 
a “don’t find” and/or “don’t eat-me” stimulus. Thus, it appears that 
the immunogenic outcome of cell death is dictated by a complex 
code of pro- and anti-immunogenic signals that must be inter-
preted by cells from the immune system including macrophages, 
DCs, and other antigen-presenting cells (Zitvogel et al., 2010). To 
date, this molecular and biochemical code has been elucidated only 
in part. For instance, the DC receptor(s) that bind(s) ecto-CRT 
remain(s) obscure. Several lines of evidence suggest that the com-
plete eradication of tumors by radio- and chemotherapy requires 
an active contribution from the immune system. Thus, the induc-
tion of immunogenic cell death represents a crucial therapeutic 
goal. During the upcoming years, molecular and cellular oncolo-
gists will have to precisely characterize the signaling cascades that 
underlie immunogenic cell death. This will drive the development 
of novel cytotoxic compounds that induce immunogenic cancer 
cell death and of agents that render immunogenic otherwise non-
immunogenic instances of cancer cell death. The clinical and thera-
peutic implications of this area of molecular and cellular oncology 
are huge.
coNclusioN
A tendency is emerging to conceive tumors as micro-ecosystems that 
are composed by a heterogeneous population of cancer (stem) cells 
as well as a plethora of distinct stromal cells, which either sustain 
or limit tumor growth at the metabolic, architectonic, trophic, and 
immunological levels. As discussed above, great advances have been 
made during the last decade toward a more refined understanding 
of cancer biology, thus generating unprecedented possibilities for 
the creation of anticancer agents that are now used in the clinics. 
For the upcoming years, we, as molecular and cell oncologists, must 
continue along similar lines to reach an ever more precise char-
acterization of the mechanisms that underlie the origin, survival, 
and therapeutic response of cancer. Only the future will tell what 
is the true potential of miRNA-based strategies over CSC-targeted, 
metabolic, and immunogenic interventions. However, it can be 
anticipated that our joint efforts will lead to the development of 
new, efficient approaches for the treatment of this dreadful disease.
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that necroptosis is a physiologically and pathologically relevant cell 
death subroutine, which can be modulated with therapeutic aims. In 
a few years, it has indeed been shown that the necrostatin-mediated 
inhibition of RIP1 in vivo exerts cytoprotective effects against neu-
rodegeneration (Yuan et al., 2003), adult brain ischemia (Degterev 
et al., 2005; Xu et al., 2010), neonatal hypoxia–ischemia (Northington 
et al., 2011), traumatic brain injury (You et al., 2008), photoreceptor 
loss-associated retinal disorders (Trichonas et al., 2011), and myo-
cardial infarction (Lim et al., 2007).
The area of necroptosis research is still in its infancy, implying 
that there is a great number of hitherto unresolved questions, in 
particular with respect to the molecular mechanisms that ignite, 
regulate, and execute this cell death subroutine. In this context, it will 
particularly interesting to elucidate the signaling cascades that are 
activated in response to different necrotic triggers and to understand 
whether there is a core machinery for the execution of regulated 
necrosis, which has already been shown to occur, at least in some 
instances, also in the absence of RIP1 (Zhang et al., 2009; Upton 
et al., 2010). A last, but not least, challenge for the upcoming years 
will be the development of novel cytotoxic chemicals that specifi-
cally induces necroptosis, which might turn out to be particularly 
valuable for cell death induction in apoptosis-refractory cancer cells.
It has been suspected for some time that cancers develop through 
three successive steps, namely (i) elimination, when immune effector 
succeed in destroying near-to-all malignant cells; (ii) equilibrium, 
when the immune system and cancer cells engage in a balanced strug-
gle; and (iii) escape, when transformed cells have succeeded in avoid-
ing immune recognition and hence proliferate in an unrestrained 
fashion (Smyth et al., 2006; Koebel et al., 2007). Escape can result 
from the loss of antigenic properties, a process called “immuno-
evasion,” or from active suppression of immune effectors, a process 
called “immunosubversion” (Zitvogel et al., 2006). There is increasing 
evidence that restoring the capacity of the immune system to control 
tumor growth may be of cardinal importance for the efficacy of 
anticancer therapies. Obeid et al. (2007) demonstrated that cancer 
cells dying in response to specific pro-apoptotic stimuli including 
anthracyclins, oxaliplatin, γ irradiation, and UVC light are able to 
elicit an immune response when injected into singenic immuno-
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